For more information, subscribe to our newsletter


Many thanks for applying with iPACT. Please read carefully this letter with an introduction to iPACT and the policy we have within our organization to ensure a transparent, dynamic and open network of people who are dedicated to improve patient care. In this document you’ll find two annexes including an application form (annex 1) and the declaration of interest form. If you want to apply for iPACT, we need both signed documents, together with the latest version of your CV. You can send this documents to We will contact you within one week to confirm your application and we will give feedback on your application within one month after application!

Best regards,
Sotiris Antoniou
Chair iPACT

1. Introduction to iPACT

iPACT (international Pharmacist Anticoagulation care taskforce) is an international expert network, which recognizes, acknowledges and supports the key role of the pharmacist in counseling and guidance of patients receiving anticoagulant therapy, in order to improve patient adherence and outcomes.

iPACT was established in January 2015 as a working group within the Stichting Davie-Ratnoff McFarlane (DRM Foundation), a non-profit organization based in the Netherlands (KvK: 62126822), directed by five dedicated experts with various skills and expertise. Based upon approved project plans in line with the vision, DRM Foundation is funding different iPACT projects.

1.1. Structure of iPACT

iPACT is a unique international network of anticoagulation experts and individuals who want to improve the care for patients receiving oral anticoagulation. iPACT has three different committees (education, science, product&innovation), to ensure the projects of iPACT are consistent with the vision & mission of DRM Foundation. Each of this committees has clear objectives to reach, which you can find on the website. Besides the three official committees, we have ‘national iPACT members’, who are officially included as iPACT member, but mainly support the national implementation of iPACT projects (eg: distribution of surveys, pilot cases, support iPACT campaigns, organization of congresses/workshops). At this time, iPACT has, representation of more than twenty countries (see website). In return, iPACT can help raise the professional profile of the national iPACT member (eg: provide national data for research, access to our network of experts, excellent speakers for national congresses, provide generic materials for campaigns…).

Please look at the website under the section ‘members’ to check if your country is already represented and involved in iPACT!

1.2. Official iPACT meetings

iPACT has two official iPACT meetings per year, at international congresses, where all iPACT members (committee members and national members) are welcome to share ideas, experiences and new initiatives. At this meetings, an update of the projects is given and iPACT members have the opportunity to share their vision. An official report is written afterwards and available on the website for members only. Unfortunately iPACT can’t provide any funding for either time or logistic support to attend the meetings, but we do our utmost best to look for partners that can support you to attend these meetings.

Please note we actively encourage all members to connect to other iPACT members to stimulate international multidisciplinary collaboration.

2. Main projects & activities

Below you find a list of the main projects, iPACT is currently working. If you are interested to participate in one or more projects, please indicate this in the application form.

1. International assessment on the knowledge and confidence of pharmacists dealing with oral anticoagulation.

2. Development of international knowledge tools & training kits for pharmacists, regarding oral anticoagulation therapy.

3. Development of international counselling tools for pharmacists regarding oral anticoagulation therapy.

4. Development of a universal guideline on the optimal care for oral anticoagulation pharmacotherapy.

5. Pilot project: screening on atrial fibrillation by community pharmacists

Besides these main projects, iPACT wants to raise awareness of the role of pharmacists on oral anticoagulant agents across the globe. In order to achieve this, we organize our own Symposia and workshops on a regular basis and publish in relevant journals (see below).

As an official representative for your country, we expect an active contribution in our network, at least to implement the work iPACT does. This can be by helping disseminate the survey through your national professional body, presenting on an international congress, help publish an article, run a workshop…

3. Code of conduct – policy on declaration of interest and intellectual property

iPACT/DRM Foundation are expected to achieve and maintain high standards of probity in the way it conducts its business. These standards include impartiality, objectivity and integrity, and the effective stewardship of funds. Managing effectively potential conflicts of interest and intellectual property is an important and essential part of in the development of tools and publications of iPACT/DRM Foundation. Without it, professionals and the public will lose confidence in our work. To avoid public concern that any such interests might prejudice the integrity or impartiality of those involved in the business of iPACT, this Code of Conduct applies to all those who are involved in or with iPACT (see ‘For who is this policy’).

This policy provides clear guidance on what interests need to be declared, who needs to declare them and when, and what action should be taken to avoid conflicts of interest influencing the management of iPACT/DRM Foundation business. Furthermore this policy provides clear guidance on the intellectual property of iPACT/DRM Foundation and the right to publish (academic) work that’s being initiated and financially supported by iPACT/DRM Foundation.

Everyone referred to in this policy should ensure that they and those for whom they have responsibility understand their obligations to disclose all relevant interests to the Chair of DRM Foundation (annex 1).

For who is this policy?

This policy applies to the following persons:

  • Board members of DRM Foundation
  • iPACT committee members
  • National iPACT members
  • Secondees (those who are seconded to iPACT from other organisations)
  • Employees of ‘contractors’ working directly or indirectly to supply evidence that is used by the guidance-producing advisory bodies.
3.1. Code of conduct – declaration of interests

How to recognize a potential conflict of interest?

A conflict of interest arises when the judgement of someone involved in the work of iPACT may be compromised by financial or other considerations set out in this policy. Another conflict of interest is when iPACT products can be commercialized by one individual or a company, based on their daily activities and commercial interests (more information in the publication and intellectual property policy).

It is also recognized that iPACT members will provide consulting services for commercial companies within the pharmaceutical sector, it does not necessarily exclude you from iPACT membership or participation in specific projects. However, you should be aware that some of these activities might exclude you from participating in specific iPACT projects or iPACT.

This policy will guide those who may have such interaction and those who have to make decisions about the circumstances in which such interaction conflicts with their work for iPACT.

Types of interests

Interests can be financial or non-financial. Financial interests can be personal or non personal. The different types of interest are explained below.

A. Personal financial interest

A personal financial interest, for the purposes of this policy, is one where there is or appears to be opportunity for personal financial gain or financial gain to a family member in the 12 months before joining an advisory committee or during the period of membership of an advisory committee. Financial interest means anything of monetary value, including payments for services, equity interests, including stocks, stock options or other ownership interests and intellectual property rights, including patents, and copyrights and royalties arising from such interests.

Some examples (not limitative):

  • Any consultancy, directorship, position in or work (which is specific to anticoagulation) in the pharmaceutical sector that attracts regular or occasional payments or benefits in kind such as hospitality.
  • All individuals, receiving payment from the commercial sector for providing consultancy services in the field of anticoagulation while working on the same topic for iPACT.
  • Any fee-paid work in the field of anticoagulation commissioned by the commercial sector for which the individual receives payment or financial benefit in kind.
  • Any shareholdings in the commercial sector held by the individual.
  • Expenses or hospitality provided by the commercial sector beyond that reasonably required for accommodation, meals and travel to attend meetings and conferences.
  • Funds which include investments in the commercial sector that are held in a portfolio where the individual has the ability to instruct the fund manager as to the composition of the fund.

B. Non-personal financial interest

A non-personal financial interest involves payment or other benefit to a department or organisation in which the individual is employed (or the individuals’ own company), but which is not received personally, in the 12 months before joining iPACT.

Some examples (not limitative):

  • A grant from a company for the running of a unit or department where the individual is employed or its own company.
  • A grant or fellowship or other payment to sponsor a post or member of staff in the unit where the individual is employed or its own company
  • The commissioning of research or other work by, or advice from, staff who work in a unit where the individual is employed, or its own company
  • Consulting services for pharmaceutical industry in the field of anticoagulation

C. Personal non-financial interest

A personal non-financial interest in the matters under consideration refers to an opinion on the matters under consideration published in the 12 months before joining iPACT.

Some examples (not limitative):

  • A clear opinion, reached as the conclusion of a research project, about the clinical and/or cost effectiveness of an intervention under review.
  • A published statement in which the individual has expressed a clear opinion about the matter under consideration, which could reasonably be interpreted as prejudicial to an objective interpretation of the evidence.
  • Holding office in a professional organization, charity or advocacy group with a direct interest in the field of anticoagulation.
  • Other reputational risks in relation to the field of anticoagulation.

What to do in case of potential conflict of interest?

If you see a potential conflict of interest, please report this to the Chair of DRM Foundation. The potential conflict of interest will be reviewed and assessed carefully within the DRM Foundation Board. They can invite you to provide more detailed information and they reserve the right to exclude you from participating in specific activities or even exclude from iPACT and iPACT meetings. In case you have doubts, please contact the Chair of DRM Foundation.

Please note that all your declarations will be held confidential and will not be distributed amongst iPACT members or on the website. In case of any proven violation of distributing this private information to third parties, your membership can be revoked at any time, without prior notice.

What about the DRM Foundation Board?

Also DRM Foundation Board need to declare potential conflict of interest and this will be published annually (for the past year) on the website.

Any potential conflicts that arise with DRM Foundation Board members should be addressed to the Chair and will follow the same procedure as other iPACT members. Off course the affected person will not be involved in this process.

4. Principles and rights for publishing and authorships of iPACT

iPACT aims to improve pharmaceutical care in people receiving anticoagulation. With this initiative, iPACT will stimulate publication of products, research results and procedures originating from iPACT. To ensure high quality and dissemination, a guidance of principles and rights for publishing and authorships was developed for all iPACT members to comply with.

Main principles

If an iPACT member wants to publish or present results/procedures/products/guidelines etc. originating from an intellectual/financial/personal contribution of iPACT, the DRM-F board should always be informed and consulted. This is to ensure:

  • High quality output of iPACT related publications;
  • All iPACT related activities are coordinated;
  • The correct use of the logo and iPACT name;
  • High exposure of the publication.

All accepted abstracts, publications and presentations will be published on the website and ResearchGate1.

Use of data

As iPACT member, you have access to all original presentations and data. Before using or analysing data that’s been collected through iPACT, the board needs to be informed and consulted. You can use your local data (in comparison with international data) for publication or presentation in your country. Whenever a joint international collaborative research project exists, the board can stipulate as a rule that the joint publication needs to be the first published or presented and subsequently the national results

If you use any data or slides as a small part of a presentation (eg slide in a workshop), coming from an iPACT publication or presentation, please always inform the chair of the scientific committee, consult the original author and reference correctly.

  • Scientific article for international peer reviewed journal requires prior board approval on content and on journal (choice of journal is recommended to discuss with the scientific committee).
  • Scientific article for national journal requires prior board approval; only local data can be used, but in comparison with international data from the same dataset.
  • Abstract for international conference requires prior board approval.
  • Abstract for national conference requires prior board approval; local data can only be used, but in comparison with international data from the same dataset.
  • Other non-scientific (international) publications require prior board approval.

All the members of the project team/working group of iPACT should be eligible for co-authorship, as long as complying with the rules of scientific publication. This means that simple participation in a meeting, where the idea has been discussed, does not necessarily imply authorship. Authors have to cumulatively:

  1. contribute to the study design;
  2. engage in data collection (when applicable);
  3. actively participate in the writing or review of the publication.

Before the writing procedures starts, the first, second, penultimate, ultimate, and corresponding authors will be assigned to avoid any conflict. All the co-authors should be in agreement with the final order.

  • All active participating iPACT members should be recognized in one way or another;
  • Each iPACT author has to declare any conflict of interest (which could potentially bias the objectivity of results);
  • All published materials, regardless of scope of journal or conference abstracts, should include after the list of authors “on behalf of iPACT”;
  • Every manuscript published should mention that funding was provided by DRM foundation, unless other funder is applicable;
  • For international publications, all the authors of publications should be iPACT members. For national publications arising as a result of the former, non-iPACT members may be invited as co-authors if they comply with the rules previously established for authorship.
  • In journals, at least the corresponding author should use an iPACT e-mail address (
Protocol to publish
  1. Inform the chair of scientific committee you want to publish or present;
  2. Define co-authorship before start writing;
  3. Send proposal to the chair of scientific committee;
  4. Agreement of the chair of scientific committee (two weeks)
  5. Chair => coordinator / board
  6. Review of the board (min. two weeks for manuscripts, one week for other publications e.g. abstracts)
  7. Approval board / coordinator => chair / author

1Please note that some journals will not allow this; in such case, simply the abstract or link to the journal may be provided.